Enoxaparin dosage adjustment in patients with severe renal failure: Antifactor Xa concentrations and safety

Pharmacotherapy

Volumn 27, Issue 10, 2007, Pages 1347-1352

  Lachish, Tamar ^a   Rudensky, Bernard ^a   Slotki, Itzchak ^a   Zevin, Shoshana ^a  

^a SHAARE ZEDEK MEDICAL CENTER   (Israel)

Author keywords

Antifactor Xa; Dosage adjustment; Enoxaparin; Renal failure

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ACUTE CORONARY SYNDROME; ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INDICATION; DRUG MONITORING; DRUG SAFETY; FEMALE; HALF LIFE TIME; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART VALVE PROSTHESIS; HEMODIALYSIS; HUMAN; LUNG EMBOLISM; MALE; PROSPECTIVE STUDY; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENOXAPARIN; FACTOR XA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, SUBCUTANEOUS; ISRAEL; KIDNEY FAILURE; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34948905817     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.10.1347     Document Type: Article

References (23)

1. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
2. Buckley MM, Sorkin EM. Enoxaparin: a review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-97.
3. Noble S, Spencer CM. Enoxaparin. A review of its clinical potential in the management of coronary artery disease. Drugs 1998;56:259-72.
4. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:188S-203.
5. Laposata M, Green D, Van Cott EM, Barrowcliffe TW, Goodnight SH, Sosolik RC. College of American Pathologists conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related Compounds, and argatroban. Arch Pathol Lab Med 1998;122:799-807.
6. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation 2004;110:392-8.
7. Ma JM, Jackevicius CA, Yeo E. Anti-Xa monitoring of enoxaparin for acute coronary syndromes in patients with renal disease. Ann Pharmacother 2004;38:1576-81.
8. Cadroy Y, Pourrat J, Baladre MF, et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 1991;63:385-90.
9. Von Visger J, Magee C. Low molecular weight heparins in renal failure. J Nephrol 2003;16:914-16.
10. Gerlach AT, Pickworth KK, Seth SK, Tanna SB, Barnes JF. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000;20:771-5.
11. The Thrombolysis in Myocardial Infarction 11A Trial Investigators. Dose-ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J Am Coll Cardiol 1997;29:1474-82.
12. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. Am Heart J 2002;143:753-9.
13. Sanderink GJ, Guimart CG, Ozoux ML, Jariwala NU, Shukla UA, Boutouyrie BX. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 2002;105:225-31.
14. Overholser BR, Brophy DF, Sowinski KM. Development of an efficient sampling strategy to predict enoxaparin pharmacokinetics in stage 5 chronic kidney disease. Ther Drug Monit 2006;28:807-12.
15. Chow SL, Zammit K, West K, Dannenhoffer M, Lopez-Candales A. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003;43:586-90.
16. Hulot JS, Montalescot G, Lechat P, Collet JP, Ankri A, Urien S. Dosing strategy in patients with renal failure receiving enoxaparin for the treatment of non-ST-segment elevation acute coronary syndrome. Clin Pharmacol Ther 2005;77:542-52.
17. Anonymous. Enoxaparin. In: Klasco RK, ed. Drugdex system. Greenwood Village, CO: Thomson Micromedex. Expires September 2007.
18. Vidal L, Shavit M, Fraser A, Paul M, Leibovici L. Systematic comparison of four sources of drug information regarding adjustment of dose for renal function. BMJ 2005;331:263-6.
19. Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006;144:673-84.
20. Alexander KP, Chen AY, Roe MT, et al. Excess dosing of antiplatelet and antithrombin agents in the treatment of non-ST-segment elevation acute coronary syndromes. JAMA 2005;294:3108-16.
21. Brophy DF, Martin EJ, Gehr TW, Carr ME Jr. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis 2004;44:270-7.
22. Merli G, Spiro TE, Olsson CG, et al. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med 2001;134:191-202.
23. Green B, Greenwood M, Saltissi D, et al. Dosing strategy for enoxaparin in patients with renal impairment presenting with acute coronary syndromes. Br J Clin Pharmacol 2005;59:281-90.